Filtered By:
Specialty: Cancer & Oncology
Condition: Heart Failure
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 141 results found since Jan 2013.
Heterogeneity of Treatment Effects for Intensive Blood Pressure Therapy by Individual Components of FRS: An Unsupervised Data-Driven Subgroup Analysis in SPRINT and ACCORD
CONCLUSION: Similar findings in patients with hypertensive with T2DM or without diabetes by multivariate subgrouping suggested that the individual components of the FRS could enrich or improve CVD risk assessment. Further research was required to clarify the potential mechanism.PMID:35187120 | PMC:PMC8850629 | DOI:10.3389/fcvm.2022.778756
Source: Cancer Control - February 21, 2022 Category: Cancer & Oncology Authors: Yaqian Wu Jianling Bai Mingzhi Zhang Fang Shao Honggang Yi Dongfang You Yang Zhao Source Type: research
Breast Cancer and Incident Cardiovascular Events. A Systematic Analysis at the Nationwide Level
CONCLUSIONS: In a large and contemporary analysis of female patients seen in French hospitals, women with history of breast cancer had higher risk of all-cause mortality, new onset heart failure and major bleeding compared to a matched cohort of women without breast cancer. In contrast, they have a reduced risk of cardiovascular mortality, MI, and stroke.PMID:35113450 | DOI:10.1111/eci.13754
Source: Clinical Genitourinary Cancer - February 3, 2022 Category: Cancer & Oncology Authors: Ying X Gue Arnaud Bisson Alexandre Bodin Julien Herbert Gregory Y H Lip Laurent Fauchier Source Type: research
Cancers, Vol. 13, Pages 6203: Acute and Long-Term Outcomes of ST-Elevation Myocardial Infarction in Cancer Patients, a & lsquo;Real World & rsquo; Analysis with 175,000 Patients
Conclusion: In this large “real world” data, prognosis after STEMI in cancer patients was markedly reduced but differed widely between cancer types. Of note, no withholding of interventional treatments in cancer patients could be observed.
Source: Cancers - December 9, 2021 Category: Cancer & Oncology Authors: Stefan A. Lange Jannik Feld Leonie K ühnemund Jeanette K öppe Lena Makowski Christiane M. Engelbertz Joachim Ger ß Patrik Dr öge Thomas Ruhnke Christian G ünster Eva Freisinger Holger Reinecke Tags: Article Source Type: research
Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
CONCLUSIONS: Our findings suggest that ABI users may be at greater risk of cardiovascular-related hospitalization compared to ENZ users, in particular for heart failure. These results provide clinicians with additional insight on the cardiovascular risks of mCRPC patients treated with NHAs in the real-world and further large studies are required to corroborate these findings.PMID:34706850 | DOI:10.1016/j.clgc.2021.08.009
Source: Clinical Prostate Cancer - October 28, 2021 Category: Cancer & Oncology Authors: Jason Hu Armen G Aprikian Marie Vanhuyse Alice Dragomir Source Type: research
The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database
CONCLUSION: CLL patients with AF are at a significantly increased risk of all-cause mortality, cardiac-related mortality, and stroke. For this population, a multidisciplinary approach should be orchestrated for better management and outcomes.PMID:34598909 | DOI:10.1016/j.clml.2021.08.006
Source: Clinical Lymphoma and Myeloma - October 2, 2021 Category: Cancer & Oncology Authors: Mohammad Ammad Ud Din Samarthkumar Thakkar Harsh Patel Hassan Saeed Syed Ather Hussain Hania Liaqat Aneeqa Zafar Sourbha S Dani Sarju Ganatra Faiz Anwer Source Type: research
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study
CONCLUSION: Our results indicate an increased risk for ischemic heart disease and arrhythmia in patients treated for more than four years with AIs. This should be considered in the risk-benefit assessment concerning endocrine therapy.PMID:34265496 | DOI:10.1016/j.breast.2021.07.004
Source: Breast - July 15, 2021 Category: Cancer & Oncology Authors: Maria Sund Miguel Garcia-Argibay Hans Garmo Johan Ahlgren Anna-Karin Wennstig Irma Fredriksson Henrik Lindman Antonis Valachis Source Type: research
Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research
Cancers, Vol. 13, Pages 2254: Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study
Conclusions: Adjuvant therapy with AI in breast cancer women aged more than 50 years is associated with increased risk of heart failure and combined CV events.
Source: Cancers - May 8, 2021 Category: Cancer & Oncology Authors: Matteo Franchi Roberta Tritto Luigi Tarantini Alessandro Navazio Giovanni Corrao Tags: Article Source Type: research
Cancers, Vol. 13, Pages 1732: Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity
Conclusions: Our studies indicate that the SP/NK1-R system is a key mediator that induces, DOX-induced, cardiac dysfunction, cardiac apoptosis, cardiac oxidative stress and cardiomyocyte hypertrophy. These studies implicate that NK-1R antagonists may serve as a novel therapeutic tool for prevention of chemotherapy induced cardiotoxicity in cancer.
Source: Cancers - April 6, 2021 Category: Cancer & Oncology Authors: Ashiq Legi Emma Rodriguez Thomas K. Eckols Cyrus Mistry Prema Robinson Tags: Article Source Type: research
Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study.
CONCLUSIONS: Women with a history of breast cancer were at increased risk of several CVDs, persisting into survivorship. Monitoring and managing cardiovascular risk throughout the long-term follow-up of women diagnosed with breast cancer should be a priority.
PMID: 33401236 [PubMed - as supplied by publisher]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - January 7, 2021 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
